Jaguar Health, Inc.
Jaguar Health, Inc. develops and commercializes plant-based prescription and non-prescription products for human and animal health, with a portfolio centered on crofelemer-based therapies and related botanical medicines. The company also uses licensing and partnership structures to extend its products and pipeline, including Mytesi, Canalevia-CA1, Gelclair, and early-stage botanical drug candidates through its Magdalena joint venture.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes Mytesi, crofelemer-based follow-on indications, and licensed human therapies such as Gelclair.
Includes Canalevia-CA1 and Neonorm products sold for companion animals and livestock.
Includes revenue from licensing arrangements such as the Gen territory agreement and other partner monetization.
Includes Magdalena and other botanical drug development efforts that are not yet commercial revenue drivers.
Products
Reported · share of revenue- Products98.4 %
- Canalevia1.3 %
- Neonorm0.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Jaguar sells mainly to distributors, wholesalers, and specialty pharmacies, which then supply patients, veterinarians, and other end users. Its human-health customers are tied to prescription access and licensing partners, while its animal-health products are sold through distribution channels serving companion animal and livestock markets. The company also relies on collaboration and license counterparties to monetize parts of its pipeline and geographic rights.
Buy Mytesi, Canalevia-CA1, and Neonorm products for onward sale into pharmacy and veterinary channels.
Dispense Mytesi to patients under prescription and support access for niche human indications.
Purchase animal products for resale to veterinarians, livestock operators, and end customers.
Monetize territory rights or development assets and provide upfront or ongoing license revenue.
Potential partners for crofelemer follow-on indications and Magdalena pipeline assets.
Strategy
Jaguar is focused on extending the commercial life of crofelemer while building new plant-based drug opportunities through internal development and partnerships. Near-term priorities include supporting Mytesi and animal product sales, advancing pipeline indications, and using collaborations such as Magdalena to broaden the addressable market without fully funding every program internally. The company is also managing liquidity by seeking financing, partnerships, and license revenue to support ongoing development and commercialization.
New indications could broaden the commercial opportunity beyond current products and create partnership value.
Upfront fees, territory licenses, and collaboration economics can fund operations without full internal commercialization costs.
Current product sales provide operating traction and validate the botanical drug platform.
The company has recurring losses and needs external funding to continue development and commercialization.
Geography
Jaguar is headquartered in the United States and generates most of its operating activity there, including product commercialization, development, and licensing. The company also has international exposure through territory licensing, a U.K.-based in-license from Venture Life, and global rights around crofelemer and related assets. Its geographic footprint matters because commercialization, regulatory approval, and partner execution are all tied to country-specific market access and FDA oversight.
Risks
Jaguar remains a development-stage pharmaceutical company with recurring losses, limited cash, and dependence on external financing, so execution and funding risk are central. Regulatory timing, especially at the FDA, can materially delay approvals and commercialization, while royalty obligations and minimum payments can pressure liquidity even if sales remain modest. The company also faces typical pharma risks around clinical success, product returns, pricing pressure, and manufacturing or supply-chain costs.
- Liquidity shortfall and financing dependenceImpact: HighLikelihood: High
The company has recurring operating losses and may not fund its plan from existing cash.
Exposure - FDA review and approval delaysImpact: HighLikelihood: Medium
Regulatory disruptions can slow submissions, meetings, inspections, and approvals.
Exposure: Pipeline timing and product launches
- Minimum royalty payment obligationsImpact: HighLikelihood: Low
Royalty interests require payments even if product sales are insufficient.
Exposure: Cash flow and debt-like burden
- Clinical development failureImpact: High
Pipeline assets depend on positive human trial and proof-of-concept results.
Exposure - Cost inflation and margin pressureImpact: Medium
Higher raw material, labor, and distribution costs can compress gross margins.
Exposure: Product revenue profitability
Accounting
Judgemental itemsRevenue comes from product sales, territory licenses, and in-license arrangements with different timing rules.
Impact: Quarterly revenue mix can be volatile
Management estimates returns for expired or defective products using historical patterns.
Impact: Can reduce reported net revenue
The company recognizes gains or losses from changes in fair value of instruments designated at FVO.
Impact: Can create non-cash earnings volatility
Exchanges and refinancing can generate gains or losses on extinguishment.
Impact: Affects operating loss comparability
Minimum royalty commitments can behave like fixed cash obligations regardless of sales.
Impact: Important for liquidity analysis and covenant-like pressure
Similar listed companies
Publicly listed companies with a comparable business focus.
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
Pacira BioSciences, Inc.
PCRX · Pharmaceutical Preparations
Pacira BioSciences is a U.S.-based biopharmaceutical company focused on non-opioid pain management products.
Jazz Pharmaceuticals plc
JAZZ · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology.
Bio-Path Holdings, Inc.
BPTH · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026